Corcept Therapeutics (NASDAQ:CORT) Given New $135.00 Price Target at Canaccord Genuity Group

Corcept Therapeutics (NASDAQ:CORT) had its target price hoisted by Canaccord Genuity Group from $110.00 to $135.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other research firms have also recently issued reports on CORT. HC Wainwright upped their price objective on Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. UBS Group set a $135.00 target price on Corcept Therapeutics in a research report on Thursday. Finally, Piper Sandler upped their target price on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.83.

Corcept Therapeutics Trading Up 2.6%

CORT stock opened at $68.38 on Thursday. The company has a market capitalization of $7.34 billion, a PE ratio of 195.38 and a beta of 0.36. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $91.00. The business’s fifty day moving average price is $47.30 and its 200 day moving average price is $52.18.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. During the same quarter last year, the company earned $0.17 EPS. Corcept Therapeutics’s revenue for the quarter was up 4.9% compared to the same quarter last year. Research analysts predict that Corcept Therapeutics will post 0.52 EPS for the current fiscal year.

Insider Transactions at Corcept Therapeutics

In other news, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $51.83, for a total transaction of $1,036,600.00. Following the sale, the insider owned 2,231 shares in the company, valued at $115,632.73. This trade represents a 89.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director G Leonard Baker, Jr. bought 100,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 86,198 shares of company stock worth $3,887,769 over the last quarter. 20.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC purchased a new position in Corcept Therapeutics in the fourth quarter valued at about $25,000. Advisory Services Network LLC purchased a new position in Corcept Therapeutics in the third quarter valued at about $25,000. Clearstead Advisors LLC raised its position in Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the period. Atlas Capital Advisors Inc. purchased a new position in Corcept Therapeutics in the fourth quarter valued at about $31,000. Finally, State of Wyoming raised its position in Corcept Therapeutics by 29.5% in the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept said it will resubmit its New Drug Application for relacorilant to treat patients with Cushing’s syndrome, reinforcing a key regulatory path for a potential commercial launch and driving renewed investor enthusiasm. Article Title
• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics from $110 to $135 and reiterated a buy rating, signaling stronger confidence in the company’s upside. Article Title
• Positive Sentiment: HC Wainwright also lifted its price target from $75 to $95 and maintained a buy rating, adding to the bullish analyst momentum around CORT. Article Title
• Positive Sentiment: Stockholders approved an expanded incentive plan and board-related measures at the 2026 annual meeting, removing a governance overhang and supporting the company’s ability to retain and incentivize talent. Article Title
• Neutral Sentiment: Short-interest data showed no meaningful change, offering little new signal for near-term trading in the stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.